BOC Sciences' Ofatumumab monoclonal antibody.
Description
Ofatumumab is a CD20-directed cytolytic monoclonal antibody with an inhibitory effect on early-stage B lymphocyte. It was approved by FDA for its use to treat patients with chronic lymphocytic leukemia (CLL) as an extended treatment or in combination with chlorambucil. It also has the thearapeutic effect on some other diseases such as follicular lymphoma